US 11,780,899 B2
Engineered proteins to enhance sensitivity of a cell to IL-2
Kenan Christopher Garcia, Menlo Park, CA (US); Sean Parker, Palo Alto, CA (US); Jonathan Sockolosky, San Francisco, CA (US); and Michael Hollander, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and Parker Institute for Cancer Immunotherapy, San Francisco, CA (US)
Appl. No. 16/769,535
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and Parker Institute for Cancer Immunotherapy, San Francisco, CA (US)
PCT Filed Dec. 5, 2018, PCT No. PCT/US2018/064086
§ 371(c)(1), (2) Date Jun. 3, 2020,
PCT Pub. No. WO2019/113221, PCT Pub. Date Jun. 13, 2019.
Claims priority of provisional application 62/595,316, filed on Dec. 6, 2017.
Prior Publication US 2020/0385438 A1, Dec. 10, 2020
Int. Cl. C07K 14/55 (2006.01); C07K 14/715 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/55 (2013.01) [C07K 14/7155 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01)] 1 Claim
 
1. A modified human CD25 polypeptide engineered to have increased affinity for IL-2, relative to native CD25 protein and affinity of the modified CD25 protein for its cognate IL-2 protein is less than 0.5 nM, comprising a set of amino acid modifications selected from the group consisting of:
(1) D4E, M25A, N27V, E29D, S39Δ, G40Δ, S41T, L42A, I118T, H120L, and K153E;
(2) M25I, N27V, E29D, L42A, I118R, H120W, and K153Q;
(3) L2Q, M25I, N27Y, L42A, I118R, H120W, and K153G;
(4) L2Q, M25V, N27Y, L42A, I118R, and H120W; and
(5) M25L, N27V, L42A, I118N, H120M, and K153G.